Download Zipped Enrolled WordPerfect HB0268.ZIP
[Introduced][Status][Bill Documents][Fiscal Note] [Bills Directory]

---

H.B. 268 Enrolled

                 

DRUG UTILIZATION REVIEW COMMITTEE
                  AMENDMENTS
                  2005 GENERAL SESSION
                  STATE OF UTAH
                  Chief Sponsor: Rebecca D. Lockhart
                  Senate Sponsor: Sheldon L. Killpack
                 
                  LONG TITLE
                  General Description:
                      This bill amends the Health Code to require public notice and comment period for
                  hearings held by the Drug Utilization Review Board.
                  Highlighted Provisions:
                      This bill:
                      .    requires 30 days advance public notice of a hearing held by the Drug Utilization
                  Review Board; and
                      .    requires the board to consider comments submitted by interested parties.
                  Monies Appropriated in this Bill:
                      None
                  Other Special Clauses:
                      None
                  Utah Code Sections Affected:
                  AMENDS:
                      26-18-105, as enacted by Chapter 273, Laws of Utah 1992
                 
                  Be it enacted by the Legislature of the state of Utah:
                      Section 1. Section 26-18-105 is amended to read:
                       26-18-105. Drug prior approval program.
                      Any drug prior approval program approved or implemented by the board shall meet the
                  following conditions:

---

                      (1) no drug may be placed on prior approval for other than medical reasons;
                      (2) the board shall hold a public hearing at least 90 days prior to placing a drug on prior
                  approval;
                      (3) notwithstanding the provisions of Section 52-4-6 , the board shall provide not less
                  than 30 days notice to the public before holding a public hearing under Subsection (2);
                      (4) the board shall consider written and oral comments submitted by interested parties
                  prior to or during the hearing held in accordance with Subsection (2);
                      [(3)] (5) the board shall provide evidence that placing a drug class on prior approval will
                  not impede quality of recipient care and that the drug class is subject to clinical abuse or misuse;
                      [(4)] (6) no later than nine months after any drug class is placed on prior approval, it
                  shall be reconsidered in a public hearing with notice as provided in Subsection (3);
                      [(5)] (7) the program shall provide either telephone or fax approval or denial at least
                  Monday through Friday, within 24 hours after receipt of the prior approval request;
                      [(6)] (8) the program shall provide for the dispensing of at least a 72-hour supply of the
                  drug in an emergency situation or on weekends;
                      [(7)] (9) the program may not be applied to prevent acceptable medical use for
                  appropriate off-label indications; and
                      [(8)] (10) any drug class placed on prior approval shall receive a majority vote by the
                  board for that placement, after meeting the requirements described in Subsections (1) through
                  [(7)] (10).

---

[Bill Documents][Bills Directory]